written on 03.04.2014
pt:
Tags:
,

Gilead readies to file Sovaldi in Japan

TAGS: ,

Gilead Sciences has reported positive topline data from its Japanese Phase III trial of sofosbuvir (Sovaldi) in combination with ribavirin for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.

Latest Report